In summary, this evaluation demonstrated that nivolumab plus ipilimumab was a cost-effective option for patients with advanced NSCLC harboring no EGFR or ALK mutations from a United States payer perspective. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.